Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3675192 | 0.82 | DRD4 (0.46) | DRD2DRD4SIGMAR1SLC6A12TMEM97 | |
| SCHEMBL6042662 | 0.82 | DRD4 (0.46) | DRD2DRD4SIGMAR1SLC6A12TMEM97 | |
| SCHEMBL4024506 | 0.81 | MEN1 (0.39) | DRD2DRD4CHRM4CHRM2CHRM5 | |
| SCHEMBL6041801 | 0.81 | ACHE (0.41) | DRD2DRD4 | |
| SCHEMBL6041799 | 0.81 | ACHE (0.41) | DRD2DRD4 | |
| SCHEMBL7531895 | 0.79 | CHRM4 (0.49) | DRD2DRD4CHRM4CHRM2CHRM5 | |
| SCHEMBL27488212 | 0.78 | MEN1 (0.44) | DRD2DRD4CHRM4CHRM2CHRM5 | |
| SCHEMBL7466045 | 0.77 | DRD2 (0.42) | DRD2DRD4CHRM4SIGMAR1SLC6A12 | |
| SCHEMBL6043641 | 0.77 | ACHE (0.42) | DRD2DRD4MEN1KMT2A | |
| SCHEMBL6043648 | 0.77 | ACHE (0.42) | DRD2DRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315701-B1 | PROCESS FOR THE RACEMISATION OF 1-BENZYL-4-(4-FLUOROPHENYL)-3-HYDROXYMETHYL-1,2,3,6-TETRAHYDROPYRIDINE TO BE USED AS INTERMEDIATE IN THE SYNTHESIS OF PAROXETINE | AESICA PHARMACEUTICALS LTD (GB) | 2009-01-28 | — | — | EP | disclosed |
| US-6949650-B2 | Process for the racemization of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2-3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine | AESICA PHARMACEUTICALS LTD. (GB) | 2005-09-27 | — | — | US | disclosed |
| US-20040014786-A1 | Procee for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2-3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine | AESICA PHARMCEUTICALS LTD. (GB) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014786-A1 | Procee for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2-3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine | HTR1E, HTR1A, CYP1B1 | DRD2 73/4885DRD4 58/4885CHRM4 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.